A secret that hides Sangamo Therapeutics Inc’s strength (NASDAQ:SGMO)

Stocks of Sangamo Therapeutics Inc (NASDAQ:SGMO) traded higher last session on Wall Street, down -3.95% to $0.81.

SGMO stock price is now 14.95% away from the 50-day moving average and 29.78% away from the 200-day moving average. The market capitalization of the company currently stands at $168.76M.

Top 5 Artificial Intelligence Stocks to Buy for 2024

By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it. According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

Sponsored

With the price target reduced from $6 to $2, RBC Capital Mkts Downgraded its rating from Outperform to Sector Perform for Sangamo Therapeutics Inc (NASDAQ: SGMO). On April 28, 2023, BofA Securities Downgraded its previous ‘Neutral’ rating to ‘Underperform’ on the stock reducing its target price from $5 to quote $1.50, while ‘Wedbush’ rates the stock as ‘Outperform’

In other news, BIOGEN INC., 10% Owner sold 6,000,000 shares of the company’s stock on Sep 26 ’23. The stock was sold for $3,000,000 at an average price of $0.50. Upon completion of the transaction, the 10% Owner now directly owns 17,652,466 shares in the company, valued at $14.3 million. A total of 4.51% of the company’s stock is owned by insiders.

During the past 12 months, Sangamo Therapeutics Inc has had a low of $0.29 and a high of $1.48. As of last week, the company has a debt-to-equity ratio of 1.23, a current ratio of 1.03, and a quick ratio of 1.03. The fifty day moving average price for SGMO is $0.7152 and a two-hundred day moving average price translates $0.6266 for the stock.

The latest earnings results from Sangamo Therapeutics Inc (NASDAQ: SGMO) was released for 2024-06-30. The net profit margin was -2033.69% and return on equity was -194.05% for SGMO. The company reported revenue of $0.36 million for the quarter, compared to $6.83 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -94.79 percent.

Related Posts